The Global Biotherapeutics Technology group at Grange Castle was established in 2006 and is part of a world-leading protein drug discovery unit within Pfizer Worldwide R&D. In 2007 and 2011, Grange Castle benefited from a major expansion of its development facility. This facility houses state-of-the-art pilot-plant, laboratories and equipment for the development of process for production of many different types of biological drugs, including proteins and vaccines. In addition, Grange Castle is also home to scientists from Pfizer's biotherapeutics research organisation working on a number of drug discovery and optimisation projects in collaboration with other Pfizer research and development sites and various partners.

Collaboration is fundamental to our strategy- we see the value in fostering relationships between industry and academia by working with more than 250 academic partners globally. In Ireland we work closely with academia through state-funded initiatives such as the Solid State Pharmaceutical Cluster (SSPC). SSPC is an innovative collaboration between academic researchers and leading pharmaceutical companies, spearheaded by the University of Limerick. The cluster provides the necessary skill set for the pharmaceutical industry and academic institutions to comprehensively investigate pharmaceutical focuses on delivering patient care and research and innovation.

In November 2012 we joined the prestigious Science Circle at the Science Gallery, Trinity College Dublin. Pfizer in partnership with other leading global companies, supports the Science Gallery's yearly programmes at Trinity College Dublin and fosters the development of science in Ireland. 

In 2014 the Science Foundation Ireland (SFI) and Pfizer announced a unique new partnership that aims to promote new biotherapeutic breakthroughs in Ireland, through academic-industry collaboration. The three year agreement will be available to qualified academic researchers from Irish universities with novel drug targeting ideas. Successful applicants will have the opportunity to work with the Pfizer Global Biotherapeutics Technology (GBT) group, including Pfizer colleagues at the Pfizer Grange Castle site, in an effort to develop the next generation of potential protein therapies. This will enable the blending of the research expertise of academics with Pfizer's drug discovery and development expertise and resources. It is hope this collaboration will identify exciting new advances that may lead to the accelerated creation of potential new therapies for unmet medical needs.